StockData
Agenus Inc logo

Agenus Inc (AGEN) stock

AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 3/30
$6.21−0.08 (-1.27%)

Close on Nov 17, 2026Market cap $279.58MP/E –Yield –

Agenus price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Agenus's price to sales ratio was 2.3× on Nov 10, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.0× to 171.1×, with a median of 0.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 10, 20262.3×+1.3
2025Dec 31, 20251.0×+0.6
2024Dec 31, 20240.4×+0.2
2023Jan 31, 20230.2×+0.0
2022Dec 30, 20220.1×+0.1
2021Dec 31, 20210.0×−171.0
2018Jan 31, 2018171.1×+16.6
2017Dec 29, 2017154.5×−134.8
2016Dec 30, 2016289.2×−61.6
2015Dec 31, 2015350.8×–

More Agenus figures

See a number that looks wrong?